PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
10421452-8	1999	An enzyme exhibiting both ChE-like substrate specificity and relative resistance to mipafox inhibition (k2/mipafox = 5.2 (+/- 1.0) x 10(-1)) was classified as atypical cholinesterase.	mipafox	84-91	RBPJ pseudogene 3	Homo sapiens	104-120
12791540-0	2003	Relative inhibitory potencies of chlorpyrifos oxon, chlorpyrifos methyl oxon, and mipafox for acetylcholinesterase versus neuropathy target esterase.	mipafox	82-89	patatin like phospholipase domain containing 6	Gallus gallus	122-148
12746135-5	2003	The I50 (20 min at 37 degrees C) for N,N"-di-2-propylphosphorodiamidofluoridate (mipafox) against hen lymphocyte NTE was 6.94 +/- 0.28 microM amperometrically and 6.02 +/- 0.71 microM colorimetrically.	mipafox	81-88	patatin like phospholipase domain containing 6	Homo sapiens	113-116
11180931-4	2001	The specificity of NTE in blood for mipafox and di-2-propyl phosphorofluoridate was close to that for neuronal NTE.	mipafox	36-43	patatin like phospholipase domain containing 6	Homo sapiens	19-22
10720708-5	2000	NTE is defined as the activity resistant to paraoxon (40 microM) and sensitive to mipafox (50 microM).	mipafox	82-89	patatin like phospholipase domain containing 6	Homo sapiens	0-3
10421491-11	1999	The target of promotion of axonopathies is thought to be similar or linked to NTE which is defined as the phenyl valerate esterase activity (PVE) in nervous tissues resistant to paraoxon and sensitive to mipafox (40 and 50 microM, pH 8.0, 20 min, respectively).	mipafox	204-211	patatin like phospholipase domain containing 6	Homo sapiens	78-81
10421492-9	1999	Under this improved sequential paraoxon/mipafox inhibition procedure S-NTE represents about 50% of total PVases while in the usual concurrent assay it was only apparently about 1-2%.	mipafox	40-47	patatin like phospholipase domain containing 6	Homo sapiens	71-74
12769600-9	2002	It is now known that this other site is similar to NTE in that it is also sensitive to mipafox but at much higher concentrations.	mipafox	87-94	patatin like phospholipase domain containing 6	Gallus gallus	51-54
10421495-4	1999	The validity of this biosensor method is confirmed by the facts that the calibration curves for NTE obtained by colorimetric and flow-through electrochemical methods were nearly identical and the titration of NTE by test inhibitor mipafox was shown to yield the same pI50 values.	mipafox	231-238	patatin like phospholipase domain containing 6	Homo sapiens	96-99
10421495-4	1999	The validity of this biosensor method is confirmed by the facts that the calibration curves for NTE obtained by colorimetric and flow-through electrochemical methods were nearly identical and the titration of NTE by test inhibitor mipafox was shown to yield the same pI50 values.	mipafox	231-238	patatin like phospholipase domain containing 6	Homo sapiens	209-212
10421452-8	1999	An enzyme exhibiting both ChE-like substrate specificity and relative resistance to mipafox inhibition (k2/mipafox = 5.2 (+/- 1.0) x 10(-1)) was classified as atypical cholinesterase.	mipafox	84-91	butyrylcholinesterase	Homo sapiens	168-182
9788582-2	1998	The direct-acting NTE inhibitors block process outgrowth by 50% or more at 50-100 microM for OBDPO and 100-200 microM for mipafox, well below their cytotoxic levels (EC50 values, 445-474 microM for OBDPO and 1021-1613 microM for mipafox).	mipafox	122-129	patatin-like phospholipase domain containing 6	Rattus norvegicus	18-21
9788582-2	1998	The direct-acting NTE inhibitors block process outgrowth by 50% or more at 50-100 microM for OBDPO and 100-200 microM for mipafox, well below their cytotoxic levels (EC50 values, 445-474 microM for OBDPO and 1021-1613 microM for mipafox).	mipafox	229-236	patatin-like phospholipase domain containing 6	Rattus norvegicus	18-21
9788582-4	1998	These findings suggest that inhibition of neurite-like and cell process outgrowth by OBDPO and mipafox may be associated with NTE inhibition.	mipafox	95-102	patatin-like phospholipase domain containing 6	Rattus norvegicus	126-129
9268605-6	1997	For example, apparent IC50 values for NTE inhibition were less than 9.6-fold the apparent IC50 values for AChE inhibition when cells were exposed to the neuropathy-inducing OPs diisopropyl phosphorofluoridate, cyclic tolyl saligenin phosphate, phenyl saligenin phosphate, mipafox, dibutyl dichlorovinyl phosphate, and di-octyl-dichlorovinyl phosphate.	mipafox	272-279	patatin like phospholipase domain containing 6	Homo sapiens	38-41
9653066-7	1998	Acetylcholinesterase activity was inhibited by mipafox (65% in the soleus; 76% in the EDL) and ecothiopate (59% in the soleus; 42% in the EDL).	mipafox	47-54	acetylcholinesterase	Mus musculus	0-20
9586870-2	1998	Dichlorvos administration significantly decreased the activities of neuropathy target esterase and other carboxylesterase viz., paraoxon resistant and mipafox and paraoxon resistant esterases.	mipafox	151-158	patatin-like phospholipase domain containing 6	Rattus norvegicus	68-94
9413546-2	1997	The esterase activity in particulate forms, resistant to paraoxon and sensitive to mipafox have been implicated in the initiation of organophosphorus-induced delayed polyneuropathy (OPIDP) and is called neuropathy target esterase (P-NTE).	mipafox	83-90	patatin like phospholipase domain containing 6	Gallus gallus	203-229
9413546-2	1997	The esterase activity in particulate forms, resistant to paraoxon and sensitive to mipafox have been implicated in the initiation of organophosphorus-induced delayed polyneuropathy (OPIDP) and is called neuropathy target esterase (P-NTE).	mipafox	83-90	patatin like phospholipase domain containing 6	Gallus gallus	233-236
9413546-11	1997	In all fractions, except brain soluble fractions, within the paraoxon resistant activity, a mipafox sensitive component was detected that is operationally considered NTE (P-NTE and S-NTE in particulate and soluble fractions, respectively).	mipafox	92-99	patatin like phospholipase domain containing 6	Gallus gallus	166-169
9413546-11	1997	In all fractions, except brain soluble fractions, within the paraoxon resistant activity, a mipafox sensitive component was detected that is operationally considered NTE (P-NTE and S-NTE in particulate and soluble fractions, respectively).	mipafox	92-99	patatin like phospholipase domain containing 6	Gallus gallus	173-176
9413546-11	1997	In all fractions, except brain soluble fractions, within the paraoxon resistant activity, a mipafox sensitive component was detected that is operationally considered NTE (P-NTE and S-NTE in particulate and soluble fractions, respectively).	mipafox	92-99	patatin like phospholipase domain containing 6	Gallus gallus	173-176
7991223-6	1994	Marked differences are noted in the duration of cholinergic symptoms and of AChE inhibition after either paraoxon and mipafox, or fenthion poisoning.	mipafox	118-125	acetylcholinesterase	Rattus norvegicus	76-80
9109545-1	1997	Neuropathy target esterase (NTE) activity is operatively defined in this work as the phenyl valerate esterase (PVase) activity resistant to 40 microM paraoxon but sensitive to 250 microM mipafox.	mipafox	187-194	patatin like phospholipase domain containing 6	Gallus gallus	0-26
9109545-1	1997	Neuropathy target esterase (NTE) activity is operatively defined in this work as the phenyl valerate esterase (PVase) activity resistant to 40 microM paraoxon but sensitive to 250 microM mipafox.	mipafox	187-194	patatin like phospholipase domain containing 6	Gallus gallus	28-31
9109545-11	1997	The chromatographic pattern and mipafox sensitivity suggest that the different tissues have a different NTE isoform composition.	mipafox	32-39	patatin like phospholipase domain containing 6	Gallus gallus	104-107
9051410-2	1997	Multiple low doses of the direct acting organophosphates, ecothiopate, paraoxon and mipafox produced persistent and additive inhibition of diaphragm acetylcholinesterase.	mipafox	84-91	acetylcholinesterase	Mus musculus	149-169
9051410-3	1997	Paraoxon and mipafox had similar effects on brain acetylcholinesterase.	mipafox	13-20	acetylcholinesterase	Mus musculus	50-70
8525498-3	1995	Mipafox (110 mumol/kg, s.c.) inhibited brain acetylcholinesterase (AChE), neuropathy target esterase (NTE) and phenylvalerate hydrolases by 58, 64 and 65%, while diaphragm AChE and phenylvalerate hydrolases were inhibited by 66 and 80%, respectively.	mipafox	0-7	acetylcholinesterase	Mus musculus	45-65
8525498-3	1995	Mipafox (110 mumol/kg, s.c.) inhibited brain acetylcholinesterase (AChE), neuropathy target esterase (NTE) and phenylvalerate hydrolases by 58, 64 and 65%, while diaphragm AChE and phenylvalerate hydrolases were inhibited by 66 and 80%, respectively.	mipafox	0-7	acetylcholinesterase	Mus musculus	67-71
8525498-3	1995	Mipafox (110 mumol/kg, s.c.) inhibited brain acetylcholinesterase (AChE), neuropathy target esterase (NTE) and phenylvalerate hydrolases by 58, 64 and 65%, while diaphragm AChE and phenylvalerate hydrolases were inhibited by 66 and 80%, respectively.	mipafox	0-7	patatin-like phospholipase domain containing 6	Mus musculus	74-100
8525498-3	1995	Mipafox (110 mumol/kg, s.c.) inhibited brain acetylcholinesterase (AChE), neuropathy target esterase (NTE) and phenylvalerate hydrolases by 58, 64 and 65%, while diaphragm AChE and phenylvalerate hydrolases were inhibited by 66 and 80%, respectively.	mipafox	0-7	patatin-like phospholipase domain containing 6	Mus musculus	102-105
8525498-3	1995	Mipafox (110 mumol/kg, s.c.) inhibited brain acetylcholinesterase (AChE), neuropathy target esterase (NTE) and phenylvalerate hydrolases by 58, 64 and 65%, while diaphragm AChE and phenylvalerate hydrolases were inhibited by 66 and 80%, respectively.	mipafox	0-7	acetylcholinesterase	Mus musculus	172-176
8525498-6	1995	Mipafox was a potent inhibitor of AChE and NTE in vitro.	mipafox	0-7	acetylcholinesterase	Mus musculus	34-38
8525498-6	1995	Mipafox was a potent inhibitor of AChE and NTE in vitro.	mipafox	0-7	patatin-like phospholipase domain containing 6	Mus musculus	43-46
7671342-1	1995	Neuropathy target esterase (NTE) activity is operatively defined in this paper as the phenyl valerate esterase activity resistant to 40 microM paraoxon but sensitive to 250 microM mipafox.	mipafox	180-187	patatin like phospholipase domain containing 6	Gallus gallus	0-26
7671342-1	1995	Neuropathy target esterase (NTE) activity is operatively defined in this paper as the phenyl valerate esterase activity resistant to 40 microM paraoxon but sensitive to 250 microM mipafox.	mipafox	180-187	patatin like phospholipase domain containing 6	Gallus gallus	28-31
8568835-2	1995	NTE is operationally defined in this article as the phenylvalerate esterase activity which is resistant to inhibition by 40 microM paraoxon and sensitive to 250 microM mipafox.	mipafox	168-175	patatin like phospholipase domain containing 6	Homo sapiens	0-3
8568835-8	1995	However, the inhibition of P-NTE by mipafox, DFP, and HDCP did not show the presence of a considerable proportion of a second component.	mipafox	36-43	patatin like phospholipase domain containing 6	Homo sapiens	29-32
8930121-9	1996	The study shows that bovine chromaffin cells possess carboxylesterase activities and respond to inhibition by paraoxon and mipafox, thus facilitating the discrimination of neuropathy target esterase.	mipafox	123-130	patatin like phospholipase domain containing 6	Bos taurus	172-198
8812209-1	1996	A method is presented for the isolation of a 155-kDa protein that possesses phenyl valerate hydrolysis activity in the presence of paraoxon but is inhibited by mipafox; the functional definition of neuropathy target esterase (neurotoxic esterase; NTE).	mipafox	160-167	patatin like phospholipase domain containing 6	Gallus gallus	198-224
7705869-2	1995	The neurotoxic esterase (NTE) activity was significantly inhibited in the brain, spinal cord and platelets of hens treated with mipafox or sarin whereas no change was noticed with parathion treatment.	mipafox	128-135	patatin like phospholipase domain containing 6	Gallus gallus	4-23
7705869-2	1995	The neurotoxic esterase (NTE) activity was significantly inhibited in the brain, spinal cord and platelets of hens treated with mipafox or sarin whereas no change was noticed with parathion treatment.	mipafox	128-135	patatin like phospholipase domain containing 6	Gallus gallus	25-28
7983680-3	1994	In the present article, a partial characterization is made of the NTE and other related PV esterases in the bovine adrenal medulla and brain; NTE sensitivity to the neurotoxic organophosphorus compound mipafox is investigated, and its subcellular distribution is studied.	mipafox	202-209	patatin like phospholipase domain containing 6	Bos taurus	66-69
7983680-3	1994	In the present article, a partial characterization is made of the NTE and other related PV esterases in the bovine adrenal medulla and brain; NTE sensitivity to the neurotoxic organophosphorus compound mipafox is investigated, and its subcellular distribution is studied.	mipafox	202-209	patatin like phospholipase domain containing 6	Bos taurus	142-145
7983680-7	1994	The mipafox inhibition curve of PV esterase activity resistant to 40 microM paraoxon in the particulate fraction of the adrenal medulla suggests that NTE activity fundamentally comprises a mipafox-sensitive component with an I50 of 6.39 microM at 30 minutes, which is similar to the value reported in hen brain.	mipafox	4-11	patatin like phospholipase domain containing 6	Bos taurus	150-153
7983680-7	1994	The mipafox inhibition curve of PV esterase activity resistant to 40 microM paraoxon in the particulate fraction of the adrenal medulla suggests that NTE activity fundamentally comprises a mipafox-sensitive component with an I50 of 6.39 microM at 30 minutes, which is similar to the value reported in hen brain.	mipafox	189-196	patatin like phospholipase domain containing 6	Bos taurus	150-153
8211998-7	1993	In fact, mipafox and methamidophos as well as certain classic protective inhibitors such as carbamate and sulfonyl fluoride form an inhibited NTE which apparently does not age and yet produces neuropathy.	mipafox	9-16	patatin like phospholipase domain containing 6	Homo sapiens	142-145
8140588-0	1994	In vivo inhibition by mipafox of soluble and particulate forms of organophosphorus neuropathy target esterase (NTE) in hen sciatic nerve.	mipafox	22-29	patatin like phospholipase domain containing 6	Homo sapiens	83-109
8140588-0	1994	In vivo inhibition by mipafox of soluble and particulate forms of organophosphorus neuropathy target esterase (NTE) in hen sciatic nerve.	mipafox	22-29	patatin like phospholipase domain containing 6	Homo sapiens	111-114
8140588-4	1994	In this work we studied the in vivo inhibition of both NTE forms with different doses of mipafox and the results were compared with sensitivity to mipafox in vitro.	mipafox	89-96	patatin like phospholipase domain containing 6	Homo sapiens	55-58
7979963-8	1994	Mipafox inhibited brain and diaphragm acetylcholinesterase and brain neuropathy target esterase.	mipafox	0-7	acetylcholinesterase	Mus musculus	38-58
7979963-8	1994	Mipafox inhibited brain and diaphragm acetylcholinesterase and brain neuropathy target esterase.	mipafox	0-7	patatin-like phospholipase domain containing 6	Mus musculus	69-95
8343998-2	1993	We have found that both acetylcholinesterase (AChE) and neuropathy target esterase (NTE) which had been inhibited with either mipafox or with a di-n-butylphosphorodiamidate could be reactivated by prolonged treatment with aqueous potassium fluoride (KF): the reaction proceeded with first-order kinetics.	mipafox	126-133	acetylcholinesterase (Cartwright blood group)	Homo sapiens	24-44
8343992-6	1993	It proved difficult to elute active NTE under non-denaturing conditions, but SDS-PAGE analysis of MNTFP-Sepharose bound proteins eluted with 2% SDS identified a 155 kDa NTE-like protein that bound in a trifluoromethylketone- or mipafox-sensitive but paraoxon-insensitive manner.	mipafox	228-235	patatin like phospholipase domain containing 6	Gallus gallus	169-172
8337699-0	1993	Modification of mipafox-induced inhibition of neuropathy target esterase in neuroblastoma cells of human origin.	mipafox	16-23	patatin like phospholipase domain containing 6	Homo sapiens	46-72
8337699-2	1993	For this study, differentiated SY-5Y cells were treated for up to 10 min with mipafox, an organophosphorus compound, and NTE inhibition was determined when cells exposed to mipafox were also exposed to the carbamate, aldicarb, and to the calcium channel blocker, verapamil.	mipafox	173-180	patatin like phospholipase domain containing 6	Homo sapiens	121-124
8337699-4	1993	Less NTE inhibition was observed when either aldicarb or verapamil was included in the incubation of SY-5Y cells with mipafox.	mipafox	118-125	patatin like phospholipase domain containing 6	Homo sapiens	5-8
8337699-6	1993	These results indicate that NTE inhibition can be detected in neuroblastoma cells, that these cells respond in a manner similar to chicken brain, and that mipafox-induced inhibition of NTE can be decreased in the presence of aldicarb or verapamil.	mipafox	155-162	patatin like phospholipase domain containing 6	Gallus gallus	28-31
8337699-6	1993	These results indicate that NTE inhibition can be detected in neuroblastoma cells, that these cells respond in a manner similar to chicken brain, and that mipafox-induced inhibition of NTE can be decreased in the presence of aldicarb or verapamil.	mipafox	155-162	patatin like phospholipase domain containing 6	Gallus gallus	185-188
8343998-2	1993	We have found that both acetylcholinesterase (AChE) and neuropathy target esterase (NTE) which had been inhibited with either mipafox or with a di-n-butylphosphorodiamidate could be reactivated by prolonged treatment with aqueous potassium fluoride (KF): the reaction proceeded with first-order kinetics.	mipafox	126-133	acetylcholinesterase (Cartwright blood group)	Homo sapiens	46-50
8343998-2	1993	We have found that both acetylcholinesterase (AChE) and neuropathy target esterase (NTE) which had been inhibited with either mipafox or with a di-n-butylphosphorodiamidate could be reactivated by prolonged treatment with aqueous potassium fluoride (KF): the reaction proceeded with first-order kinetics.	mipafox	126-133	patatin like phospholipase domain containing 6	Homo sapiens	56-82
8343998-2	1993	We have found that both acetylcholinesterase (AChE) and neuropathy target esterase (NTE) which had been inhibited with either mipafox or with a di-n-butylphosphorodiamidate could be reactivated by prolonged treatment with aqueous potassium fluoride (KF): the reaction proceeded with first-order kinetics.	mipafox	126-133	patatin like phospholipase domain containing 6	Homo sapiens	84-87
8343998-5	1993	We conclude that it is likely that the mipafox-enzyme bond in inhibited NTE and AChE is relatively strong but that aging has not occurred.	mipafox	39-46	patatin like phospholipase domain containing 6	Homo sapiens	72-75
8343998-5	1993	We conclude that it is likely that the mipafox-enzyme bond in inhibited NTE and AChE is relatively strong but that aging has not occurred.	mipafox	39-46	acetylcholinesterase (Cartwright blood group)	Homo sapiens	80-84
1471154-2	1992	At doses of 18-182 micrograms mipafox and 9-110 micrograms DFP, inhibition of neuropathy target esterase (NTE) for the treated segment was over 80%, whereas for the adjacent distal and proximal segments inhibition was under 40%, 15 min after application.	mipafox	30-37	patatin like phospholipase domain containing 6	Gallus gallus	78-104
1471154-2	1992	At doses of 18-182 micrograms mipafox and 9-110 micrograms DFP, inhibition of neuropathy target esterase (NTE) for the treated segment was over 80%, whereas for the adjacent distal and proximal segments inhibition was under 40%, 15 min after application.	mipafox	30-37	patatin like phospholipase domain containing 6	Gallus gallus	106-109
3753463-5	1986	At 25 degrees C, the Km of NTE for phenyl valerate was determined to be about 2.4 X 10(-3) M. Secondly, the kinetic constants of NTE for mipafox were measured at both 25 degrees C and 37 degrees C. With either phenyl valerate or phenyl phenylacetate as substrate, the Km at 37 degrees C was determined to be about 1.8 X 10(-4) M, and the phosphorylation constant (k2) was about 1.1 min-1.	mipafox	137-144	patatin like phospholipase domain containing 6	Homo sapiens	129-132
2051750-2	1991	NTE activity is calculated from the rate of phenyl valerate hydrolysis resistant to paraoxon and sensitive to mipafox inhibition under specified conditions of inhibitor concentrations, pH, temperature, and incubation times with inhibitors and substrate.	mipafox	110-117	patatin like phospholipase domain containing 6	Homo sapiens	0-3
2703698-1	1989	We developed a histochemical method for localizing neurotoxic esterase (NTE), defined as the phenylvalerate (PV)-hydrolyzing esterase that is resistant to 40 microM paraoxon (A) but inactivated by paraoxon plus 50 microM mipafox (B).	mipafox	221-228	patatin like phospholipase domain containing 6	Gallus gallus	51-70
2703698-1	1989	We developed a histochemical method for localizing neurotoxic esterase (NTE), defined as the phenylvalerate (PV)-hydrolyzing esterase that is resistant to 40 microM paraoxon (A) but inactivated by paraoxon plus 50 microM mipafox (B).	mipafox	221-228	patatin like phospholipase domain containing 6	Gallus gallus	72-75
3579980-8	1987	Mipafox pI50 values obtained from complete titration curves carried out on NTE solubilized in Triton X-100, sodium cholate, or sodium cholate/asolectin were indistinguishable from the value for native enzyme from brain homogenate.	mipafox	0-7	patatin like phospholipase domain containing 6	Gallus gallus	75-78
3190748-2	1988	Assay of neuropathy target esterase (NTE) which accounts for about 70% of paraoxon-resistant phenyl valerate (PV) esterase activity of hen brain depends on the fact that it is selectively inhibited by mipafox.	mipafox	201-208	patatin like phospholipase domain containing 6	Homo sapiens	9-35
3190748-2	1988	Assay of neuropathy target esterase (NTE) which accounts for about 70% of paraoxon-resistant phenyl valerate (PV) esterase activity of hen brain depends on the fact that it is selectively inhibited by mipafox.	mipafox	201-208	patatin like phospholipase domain containing 6	Homo sapiens	37-40
3753463-8	1986	The fact that the Michaelis model fit the data significantly better than either of the other two models indicates that the higher apparent Ki values that occur with low concentrations of mipafox are due to formation of Michaelis complex at high concentrations, rather than because of the presence of two NTE isoenzymes, as has been suggested by other investigators.	mipafox	187-194	patatin like phospholipase domain containing 6	Homo sapiens	304-307
3699331-7	1986	In conclusion, NTE from both species was very similar, with the mipafox I50 for rat NTE within the range of reported values for chicken and human NTE, and the inhibitor parameters of the chicken NTE assay were applicable for the rat NTE assay.	mipafox	64-71	patatin like phospholipase domain containing 6	Gallus gallus	84-87
3699331-7	1986	In conclusion, NTE from both species was very similar, with the mipafox I50 for rat NTE within the range of reported values for chicken and human NTE, and the inhibitor parameters of the chicken NTE assay were applicable for the rat NTE assay.	mipafox	64-71	patatin like phospholipase domain containing 6	Homo sapiens	84-87
3699331-7	1986	In conclusion, NTE from both species was very similar, with the mipafox I50 for rat NTE within the range of reported values for chicken and human NTE, and the inhibitor parameters of the chicken NTE assay were applicable for the rat NTE assay.	mipafox	64-71	patatin like phospholipase domain containing 6	Gallus gallus	84-87
3699331-7	1986	In conclusion, NTE from both species was very similar, with the mipafox I50 for rat NTE within the range of reported values for chicken and human NTE, and the inhibitor parameters of the chicken NTE assay were applicable for the rat NTE assay.	mipafox	64-71	patatin like phospholipase domain containing 6	Gallus gallus	84-87
7278155-4	1981	Because of the commercial unavailability and high toxicity of mipafox, which is usually used as the selective inhibitor for assaying NTE, leptophosoxon was used as an alternative to mipafox.	mipafox	62-69	patatin like phospholipase domain containing 6	Gallus gallus	133-136
6623525-2	1983	Enzyme activity from chick embryo brain with properties of neurotoxic esterase (NTE, insensitive to 40 microM paraoxon, sensitive to 50 microM mipafox) migrated in a 9S peak.	mipafox	143-150	patatin like phospholipase domain containing 6	Gallus gallus	80-83
7078105-0	1982	A kinetic study on the inhibition of hen brain neurotoxic esterase by mipafox.	mipafox	70-77	patatin like phospholipase domain containing 6	Homo sapiens	47-66
7078105-2	1982	The technique was used to determine the bimolecular rate (ki), phosphorylation (k2), and affinity (Kd) constants for the reaction of hen brain microsomal NTE with mipafox.	mipafox	163-170	patatin like phospholipase domain containing 6	Homo sapiens	154-157
7078105-4	1982	The affinity and phosphorylation constants, Kd and k2, for the reaction of hen brain microsomal NTE with mipafox, were found to be 6.72 x 10(-5) M and 3.23 min-1, respectively.	mipafox	105-112	patatin like phospholipase domain containing 6	Homo sapiens	96-99
7078105-4	1982	The affinity and phosphorylation constants, Kd and k2, for the reaction of hen brain microsomal NTE with mipafox, were found to be 6.72 x 10(-5) M and 3.23 min-1, respectively.	mipafox	105-112	CD59 molecule (CD59 blood group)	Homo sapiens	156-161
4049405-4	1985	We report here that paraoxon is apparently able to reduce the rate of inhibition of both neurotoxic esterase isozymes by mipafox in a concentration-dependent manner.	mipafox	121-128	patatin like phospholipase domain containing 6	Homo sapiens	89-108
4049405-5	1985	As a result, the rate of inhibition of NTE by mipafox is greater when sequential, rather than concurrent, preinhibition is utilized.	mipafox	46-53	patatin like phospholipase domain containing 6	Homo sapiens	39-42
7082366-3	1982	Included among the paraoxon-resistant esterases is neurotoxic esterase (NTE), which is inhibited in vivo and in vitro by certain organophosphorus compounds, such as mipafox, which cause delayed neurotoxicity.	mipafox	165-172	patatin like phospholipase domain containing 6	Gallus gallus	51-70
7082366-3	1982	Included among the paraoxon-resistant esterases is neurotoxic esterase (NTE), which is inhibited in vivo and in vitro by certain organophosphorus compounds, such as mipafox, which cause delayed neurotoxicity.	mipafox	165-172	patatin like phospholipase domain containing 6	Gallus gallus	72-75
7278155-5	1981	Results indicated that the NTE fraction of hen brain microsomal PV-hydrolyzing activity is the same target for either mipafox or leptophosoxon.	mipafox	118-125	patatin like phospholipase domain containing 6	Gallus gallus	27-30
30088187-7	2019	Liraglutide protected cells against the neurotoxicity of mipafox by increasing neuritogenesis, the uptake of glucose, the levels of cytoskeleton proteins, and synaptic-plasticity modulators, besides decreasing the pro-inflammatory cytokine interleukin 1beta and caspase-3 activity.	mipafox	57-64	interleukin 1 beta	Homo sapiens	240-257
30088187-7	2019	Liraglutide protected cells against the neurotoxicity of mipafox by increasing neuritogenesis, the uptake of glucose, the levels of cytoskeleton proteins, and synaptic-plasticity modulators, besides decreasing the pro-inflammatory cytokine interleukin 1beta and caspase-3 activity.	mipafox	57-64	caspase 3	Homo sapiens	262-271
26838044-0	2017	Butyrylcholinesterase identification in a phenylvalerate esterase-enriched fraction sensitive to low mipafox concentrations in chicken brain.	mipafox	101-108	butyrylcholinesterase	Gallus gallus	0-21
30176330-8	2018	Four enzymatic components (CP1, CP2, CP3 and CP4) were discriminated in cholinesterase activity in the membrane fraction according to their sensitivity to irreversible inhibitors mipafox, paraoxon, PMSF and iso-OMPA.	mipafox	179-186	butyrylcholinesterase	Gallus gallus	72-86
27939611-3	2017	Mipafox (20muM) decreased cellular differentiation and the expression of neurofilament 200 (NF-200), growth associated- (GAP-43) and synaptic proteins (synapsin I and synaptophysin); whereas paraoxon (300muM) induced no effect on cellular differentiation, but significant decrease of NF-200, GAP-43, synapsin I and synaptophysin as compared to controls.	mipafox	0-7	growth associated protein 43	Homo sapiens	121-127
27939611-3	2017	Mipafox (20muM) decreased cellular differentiation and the expression of neurofilament 200 (NF-200), growth associated- (GAP-43) and synaptic proteins (synapsin I and synaptophysin); whereas paraoxon (300muM) induced no effect on cellular differentiation, but significant decrease of NF-200, GAP-43, synapsin I and synaptophysin as compared to controls.	mipafox	0-7	synapsin I	Homo sapiens	152-162
27939611-3	2017	Mipafox (20muM) decreased cellular differentiation and the expression of neurofilament 200 (NF-200), growth associated- (GAP-43) and synaptic proteins (synapsin I and synaptophysin); whereas paraoxon (300muM) induced no effect on cellular differentiation, but significant decrease of NF-200, GAP-43, synapsin I and synaptophysin as compared to controls.	mipafox	0-7	synaptophysin	Homo sapiens	167-180
27939611-3	2017	Mipafox (20muM) decreased cellular differentiation and the expression of neurofilament 200 (NF-200), growth associated- (GAP-43) and synaptic proteins (synapsin I and synaptophysin); whereas paraoxon (300muM) induced no effect on cellular differentiation, but significant decrease of NF-200, GAP-43, synapsin I and synaptophysin as compared to controls.	mipafox	0-7	growth associated protein 43	Homo sapiens	292-298
27939611-3	2017	Mipafox (20muM) decreased cellular differentiation and the expression of neurofilament 200 (NF-200), growth associated- (GAP-43) and synaptic proteins (synapsin I and synaptophysin); whereas paraoxon (300muM) induced no effect on cellular differentiation, but significant decrease of NF-200, GAP-43, synapsin I and synaptophysin as compared to controls.	mipafox	0-7	synapsin I	Homo sapiens	300-310
27939611-3	2017	Mipafox (20muM) decreased cellular differentiation and the expression of neurofilament 200 (NF-200), growth associated- (GAP-43) and synaptic proteins (synapsin I and synaptophysin); whereas paraoxon (300muM) induced no effect on cellular differentiation, but significant decrease of NF-200, GAP-43, synapsin I and synaptophysin as compared to controls.	mipafox	0-7	synaptophysin	Homo sapiens	315-328
28862523-6	2017	Only nimodipine inhibited reduction of synaptophysin levels produced by mipafox.	mipafox	72-79	synaptophysin	Homo sapiens	39-52
25743373-0	2016	Resolving pathways of interaction of mipafox and a sarin analog with human acetylcholinesterase by kinetics, mass spectrometry and molecular modeling approaches.	mipafox	37-44	acetylcholinesterase (Cartwright blood group)	Homo sapiens	75-95
27117976-4	2016	We tested, in D3 mouse embryonic stem cells under differentiation, the effects of the NTE inhibition by the OPs mipafox, CPS and its main active metabolite chlorpyrifos-oxon (CPO) on the expression of genes Vegfa, Bcl2, Amot, Nes and Jun, previously reported to be under- or overexpressed after Pnpla6 silencing in this same cellular model.	mipafox	112-119	patatin-like phospholipase domain containing 6	Mus musculus	86-89
27117976-5	2016	Mipafox did not significantly alter the expression of such genes at concentrations that significantly inhibited NTE.	mipafox	0-7	patatin-like phospholipase domain containing 6	Mus musculus	112-115
27475862-7	2016	These phenotypic effects were not reproduced when NTE esterase activity was inhibited by neuropathic OP mipafox instead of being silenced at the genetic level.	mipafox	104-111	patatin like phospholipase domain containing 6	Homo sapiens	50-53
27507601-3	2016	In this work, four enzymatic components (CS1, CS2, CS3 and CS4) of cholinesterase activity have been discriminated in soluble fraction, according to their sensitivity to irreversible inhibitors mipafox, paraoxon, PMSF and iso-OMPA and to reversible inhibitors ethopropazine and BW284C51.	mipafox	194-201	butyrylcholinesterase	Gallus gallus	67-81
25743373-5	2016	Here, our goal was to study oxime reactivation and aging reactions of human AChE inhibited by mipafox or a sarin analog (Flu-MPs, fluorescent methylphosphonate).	mipafox	94-101	acetylcholinesterase (Cartwright blood group)	Homo sapiens	76-80
25596135-6	2015	Trichlorfon and mipafox presented the lowest percentage of reactivation of inhibited NTE and the lowest ratio IC50 NTE/IC50 AChE.	mipafox	16-23	patatin like phospholipase domain containing 6	Homo sapiens	85-88
25910916-6	2015	Mipafox had the lowest IC50 and induced the highest percentage of aging of NTE among the OPs evaluated.	mipafox	0-7	patatin like phospholipase domain containing 6	Homo sapiens	75-78
25910916-8	2015	Concentrations of mipafox and fenamiphos which inhibited at least 70% of NTE were also able to reduce neurite outgrowth.	mipafox	18-25	patatin like phospholipase domain containing 6	Homo sapiens	73-76
25596135-6	2015	Trichlorfon and mipafox presented the lowest percentage of reactivation of inhibited NTE and the lowest ratio IC50 NTE/IC50 AChE.	mipafox	16-23	patatin like phospholipase domain containing 6	Homo sapiens	115-118
25596135-6	2015	Trichlorfon and mipafox presented the lowest percentage of reactivation of inhibited NTE and the lowest ratio IC50 NTE/IC50 AChE.	mipafox	16-23	acetylcholinesterase (Cartwright blood group)	Homo sapiens	124-128
19620706-3	2009	The activity of neuropathy target esterase is significantly inhibited by phenylmethylsulfonyl fluoride and paraoxon plus mipafox but not by paraoxon alone.	mipafox	121-128	patatin-like phospholipase domain containing 6	Mus musculus	16-42
22503708-2	2012	In this work, we evaluate and characterize the interaction (inhibition, reactivation and "ongoing inhibition") of two model compounds: paraoxon (non-neuropathy-inducer) and mipafox (neuropathy-inducer), with esterases of chicken brain membranes, an animal model, tissue and fractions, where neuropathy target esterase (NTE) was first described and isolated.	mipafox	173-180	patatin like phospholipase domain containing 6	Gallus gallus	291-317
22503708-2	2012	In this work, we evaluate and characterize the interaction (inhibition, reactivation and "ongoing inhibition") of two model compounds: paraoxon (non-neuropathy-inducer) and mipafox (neuropathy-inducer), with esterases of chicken brain membranes, an animal model, tissue and fractions, where neuropathy target esterase (NTE) was first described and isolated.	mipafox	173-180	patatin like phospholipase domain containing 6	Gallus gallus	319-322
20603202-4	2010	Therefore, the present study was carried out to test the hypothesis that NTE in cultured skin fibroblasts from NTE-MND subjects also exhibit altered enzymological properties assessed by SA and IC(50) values of mipafox (MIP) and chlorpyrifos oxon (CPO).	mipafox	210-217	patatin like phospholipase domain containing 6	Homo sapiens	73-76
20603202-4	2010	Therefore, the present study was carried out to test the hypothesis that NTE in cultured skin fibroblasts from NTE-MND subjects also exhibit altered enzymological properties assessed by SA and IC(50) values of mipafox (MIP) and chlorpyrifos oxon (CPO).	mipafox	219-222	patatin like phospholipase domain containing 6	Homo sapiens	73-76
17913405-13	2007	The inhibition curve of mipafox on NTE activity of cNEST in mammalian cells was also reported here.	mipafox	24-31	patatin like phospholipase domain containing 6	Homo sapiens	35-38
17323978-3	2007	However, recent evidence has shown that acetylcholinesterase (AChE) and the catalytic domain of human neuropathy target esterase (NEST) undergo aging by alternative mechanisms following their inhibition with N,N"-diisopropylphosphorodiamidofluoridate (mipafox, MIP).	mipafox	252-259	acetylcholinesterase (Cartwright blood group)	Homo sapiens	40-60
17663017-1	2007	Brain neuropathy target esterase (NTE), associated with organophosphorus (OP)-induced delayed neuropathy, has the same OP inhibitor sensitivity and specificity profiles assayed in the classical way (paraoxon-resistant, mipafox-sensitive hydrolysis of phenyl valerate) or with lysophosphatidylcholine (LysoPC) as the substrate.	mipafox	219-226	patatin like phospholipase domain containing 6	Homo sapiens	6-32
17663017-1	2007	Brain neuropathy target esterase (NTE), associated with organophosphorus (OP)-induced delayed neuropathy, has the same OP inhibitor sensitivity and specificity profiles assayed in the classical way (paraoxon-resistant, mipafox-sensitive hydrolysis of phenyl valerate) or with lysophosphatidylcholine (LysoPC) as the substrate.	mipafox	219-226	patatin like phospholipase domain containing 6	Homo sapiens	34-37
17323978-3	2007	However, recent evidence has shown that acetylcholinesterase (AChE) and the catalytic domain of human neuropathy target esterase (NEST) undergo aging by alternative mechanisms following their inhibition with N,N"-diisopropylphosphorodiamidofluoridate (mipafox, MIP).	mipafox	252-259	acetylcholinesterase (Cartwright blood group)	Homo sapiens	62-66
17323978-3	2007	However, recent evidence has shown that acetylcholinesterase (AChE) and the catalytic domain of human neuropathy target esterase (NEST) undergo aging by alternative mechanisms following their inhibition with N,N"-diisopropylphosphorodiamidofluoridate (mipafox, MIP).	mipafox	252-259	patatin like phospholipase domain containing 6	Homo sapiens	102-128
16963094-1	2007	Organophosphorus compounds (OP) such as phenyl saligenin phosphate (PSP) and mipafox (MPX) which cause delayed neuropathy, inhibit neuropathy target esterase (NTE), while OPs such as paraoxon (PXN) react more readily with acetylcholinesterase.	mipafox	77-84	patatin-like phospholipase domain containing 6	Mus musculus	131-157
16963094-1	2007	Organophosphorus compounds (OP) such as phenyl saligenin phosphate (PSP) and mipafox (MPX) which cause delayed neuropathy, inhibit neuropathy target esterase (NTE), while OPs such as paraoxon (PXN) react more readily with acetylcholinesterase.	mipafox	77-84	patatin-like phospholipase domain containing 6	Mus musculus	159-162
17207828-7	2007	When phenyl benzoate (PB) was used as substrate, about 65% of total activity was resistant to the non-promoter mipafox (up to 0.5 mM, 20 min, pH 8.0), that inhibits NTE and other esterases.	mipafox	111-118	patatin like phospholipase domain containing 6	Homo sapiens	165-168
16963094-1	2007	Organophosphorus compounds (OP) such as phenyl saligenin phosphate (PSP) and mipafox (MPX) which cause delayed neuropathy, inhibit neuropathy target esterase (NTE), while OPs such as paraoxon (PXN) react more readily with acetylcholinesterase.	mipafox	86-89	patatin-like phospholipase domain containing 6	Mus musculus	131-157
16963094-1	2007	Organophosphorus compounds (OP) such as phenyl saligenin phosphate (PSP) and mipafox (MPX) which cause delayed neuropathy, inhibit neuropathy target esterase (NTE), while OPs such as paraoxon (PXN) react more readily with acetylcholinesterase.	mipafox	86-89	patatin-like phospholipase domain containing 6	Mus musculus	159-162
16963094-4	2007	In cortical and cerebellar granule neurons and astrocytes, [(14)C]GroPCho labeling was inhibited by PSP and MPX: phenyl dipentylphosphinate (PDPP), a non-neuropathic NTE inhibitor, was more potent, while PXN, was substantially less so.	mipafox	108-111	patatin-like phospholipase domain containing 6	Mus musculus	166-169
17184757-6	2007	Immediately after mipafox treatment NTE activity represented 3% of the control (6.7+/-1.9mU/10(6) cells).	mipafox	18-25	patatin like phospholipase domain containing 6	Bos taurus	36-39
17184757-0	2007	Recovery of neuropathy target esterase activity after inhibition with mipafox and O-hexyl O-2,5-dichlorophenyl phosphoramidate in bovine chromaffin cell cultures.	mipafox	70-77	patatin like phospholipase domain containing 6	Bos taurus	12-38
16122834-6	2005	Mipafox, a neurotoxic organophosphate, was shown to block process outgrowth and differentiation in cells that have lowered NTE activity due to RNA interference, suggesting that mipafox may interact with other molecules to exert its effect in this context.	mipafox	0-7	patatin like phospholipase domain containing 6	Homo sapiens	123-126
16766477-5	2006	The anti-AChE activity of paraoxon (maximum 3 muM) and anti-NTE activity of mipafox (250 muM) in SY5Y cells were prevented by biodegradation with OPH.	mipafox	76-83	patatin like phospholipase domain containing 6	Homo sapiens	60-63
16766477-5	2006	The anti-AChE activity of paraoxon (maximum 3 muM) and anti-NTE activity of mipafox (250 muM) in SY5Y cells were prevented by biodegradation with OPH.	mipafox	76-83	acylaminoacyl-peptide hydrolase	Homo sapiens	146-149
16766477-6	2006	Anti-AChE activities of mipafox, methyl parathion, and demeton-S were partially ameliorated, depending on OP concentration.	mipafox	24-31	acetylcholinesterase (Cartwright blood group)	Homo sapiens	5-9
16766477-8	2006	However, NF200 levels rose in cells treated during late differentiation with OPH-treated mipafox.	mipafox	89-96	acylaminoacyl-peptide hydrolase	Homo sapiens	77-80
16485911-0	2006	Aging of mipafox-inhibited human acetylcholinesterase proceeds by displacement of both isopropylamine groups to yield a phosphate adduct.	mipafox	9-16	acetylcholinesterase (Cartwright blood group)	Homo sapiens	33-53
16485911-3	2006	Recently, however, it has been shown that the catalytic domain of human NTE inhibited by N,N"-diisopropylphosphorodiamidofluoridate (mipafox, MIP) ages by deprotonation.	mipafox	133-140	patatin like phospholipase domain containing 6	Homo sapiens	72-75
16122834-6	2005	Mipafox, a neurotoxic organophosphate, was shown to block process outgrowth and differentiation in cells that have lowered NTE activity due to RNA interference, suggesting that mipafox may interact with other molecules to exert its effect in this context.	mipafox	177-184	patatin like phospholipase domain containing 6	Homo sapiens	123-126
15205030-3	2004	Mipafox, which induces OPIDN, increased NF200 protein expression in SY5Y cells differentiated with human recombinant beta-nerve growth factor (NGF, 20 ng/ml) in a concentration-dependent manner, compared to NGF controls, when SY5Y cells were exposed to 0.3 or 30 microM mipafox during the last 5 days of neurite extension (experimental set A).	mipafox	0-7	nerve growth factor	Homo sapiens	117-141
15205030-3	2004	Mipafox, which induces OPIDN, increased NF200 protein expression in SY5Y cells differentiated with human recombinant beta-nerve growth factor (NGF, 20 ng/ml) in a concentration-dependent manner, compared to NGF controls, when SY5Y cells were exposed to 0.3 or 30 microM mipafox during the last 5 days of neurite extension (experimental set A).	mipafox	0-7	nerve growth factor	Homo sapiens	143-146
15205030-3	2004	Mipafox, which induces OPIDN, increased NF200 protein expression in SY5Y cells differentiated with human recombinant beta-nerve growth factor (NGF, 20 ng/ml) in a concentration-dependent manner, compared to NGF controls, when SY5Y cells were exposed to 0.3 or 30 microM mipafox during the last 5 days of neurite extension (experimental set A).	mipafox	0-7	nerve growth factor	Homo sapiens	207-210
15177651-2	2004	Organophosphorus-induced polyneuropathy is a syndrome related to the inhibition and further modification by organophosphorus compounds of NTE (a protein that displays phenyl valerate esterase activity resistant to mipafox and sensitive to paraoxon).	mipafox	214-221	patatin like phospholipase domain containing 6	Bos taurus	138-141
15177651-8	2004	We conclude that NTE could be assayed in this system by only using one inhibitor (mipafox) instead of two (paraoxon and mipafox).	mipafox	82-89	patatin like phospholipase domain containing 6	Bos taurus	17-20
15177651-8	2004	We conclude that NTE could be assayed in this system by only using one inhibitor (mipafox) instead of two (paraoxon and mipafox).	mipafox	120-127	patatin like phospholipase domain containing 6	Bos taurus	17-20
15177652-10	2004	The model equation with a fixed AR value was again applied (step 3) to deduce the second-order inhibition rate constants (k1=2.6 x 10(6) M-1 min-1 and k2=0.28 x 10(6) M-1 min-1), being conserved consistently throughout all mipafox concentrations.	mipafox	223-230	myoregulin	Homo sapiens	137-146
15052610-6	2004	Cholinesterase activities (with acetylthiocholine [ChE-A] and butyrylthiocholine [ChE-B] as substrates) in human plasma were measured photometrically in the presence of different MPFX concentrations and the IC(50) was calculated.	mipafox	179-183	butyrylcholinesterase	Homo sapiens	0-14
15035642-0	2004	The mipafox-inhibited catalytic domain of human neuropathy target esterase ages by reversible proton loss.	mipafox	4-11	patatin like phospholipase domain containing 6	Homo sapiens	48-74
15035642-3	2004	N,N"-Diisopropylphosphorodiamidofluoridate (mipafox, MIP)-inhibited NTE has been thought to age quickly; however, it can be reactivated under acidic conditions.	mipafox	44-51	major intrinsic protein of lens fiber	Homo sapiens	53-56
15035642-3	2004	N,N"-Diisopropylphosphorodiamidofluoridate (mipafox, MIP)-inhibited NTE has been thought to age quickly; however, it can be reactivated under acidic conditions.	mipafox	44-51	patatin like phospholipase domain containing 6	Homo sapiens	68-71